DAKGESUNDHEIT
A United Kingdom buyer, with 25 published contracts, worth £102.3m, most recently 3 months ago.
Top 5 suppliers won 100% of awarded value — £132.3m of £132.3m across 21 awards.
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abrocitinib (ATC D11AH08) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will involve formal procurement proced
The DAK-Gesundheit is seeking pharmaceutical companies to enter into a non-exclusive discount agreement for the drug Umeclidinium (ATC R03BB07) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will follow the formal
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication containing the active ingredients Tafluprost and Timolol (ATC S01ED70). This agreement is in accordance with § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical com
The German Social Code allows health insurance funds and pharmaceutical companies to enter into framework discount agreements for medications covered by statutory health insurance. In accordance with the relevant legal provisions for public procurement, a regular process of substance-related formal
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Cyanocobalamin (ATC B03BA01) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from July 1, 2025, to June 30, 2027, with an option to extend for an additional 12 months.
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the pharmaceutical substances Dolutegravir and Rilpivirine, classified under ATC J05AR21. This agreement will be effective from July 1, 2025, to June 30, 2027. The contract is part of a framework that allows
